DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.1016/j.bcmd.2014.07.009
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2015
- Creator
-
Logan, Gemma E.
Mor-Vaknin, Nirit
Braunschweig, Till
Jost, Edgar
Schmidt, Pia Verena
Markovitz, David M.
Mills, Ken I.
Kappes, Ferdinand
Percy, Melanie J.
- DOI
-
10.18154/RWTH-CONV-090423
- URN
-
urn:nbn:de:101:1-2018110505551734149364
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Logan, Gemma E.
- Mor-Vaknin, Nirit
- Braunschweig, Till
- Jost, Edgar
- Schmidt, Pia Verena
- Markovitz, David M.
- Mills, Ken I.
- Kappes, Ferdinand
- Percy, Melanie J.
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2015
Other Objects (12)
The DEK oncogene and its implications in cellular networks
Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML)
Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Role of the DEK oncogene in the development of squamous cell carcinoma
Deregulated circular RNA expression in acute myeloid leukemia (AML)
Oncogene : including Oncogene reviews
A stochastic model of myeloid cell lineages in hematopoiesis and pathway mutations in acute myeloid leukemia
Context-specific Roles of Infections and Interferons in Hematopoiesis and Myeloid Neoplasms
GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia
Acute myeloid leukemia (AML) immunotherapy with genetically programmed dendritic cells
GABP is necessary for stem/progenitor cell maintenance and myeloid differentiation in human hematopoiesis and chronic myeloid leukemia
The DEK oncogene and its implications in cellular networks
Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML)
Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Role of the DEK oncogene in the development of squamous cell carcinoma
Deregulated circular RNA expression in acute myeloid leukemia (AML)
Oncogene : including Oncogene reviews
A stochastic model of myeloid cell lineages in hematopoiesis and pathway mutations in acute myeloid leukemia
Context-specific Roles of Infections and Interferons in Hematopoiesis and Myeloid Neoplasms
GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia
Acute myeloid leukemia (AML) immunotherapy with genetically programmed dendritic cells
GABP is necessary for stem/progenitor cell maintenance and myeloid differentiation in human hematopoiesis and chronic myeloid leukemia
The DEK oncogene and its implications in cellular networks
Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML)
Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Role of the DEK oncogene in the development of squamous cell carcinoma
Deregulated circular RNA expression in acute myeloid leukemia (AML)
Oncogene : including Oncogene reviews
A stochastic model of myeloid cell lineages in hematopoiesis and pathway mutations in acute myeloid leukemia
Context-specific Roles of Infections and Interferons in Hematopoiesis and Myeloid Neoplasms
GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia
Acute myeloid leukemia (AML) immunotherapy with genetically programmed dendritic cells